Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

7(87.5%)

Phase 2

1(12.5%)

8Total

Phase 1(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03896568Phase 1Recruiting

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Role: collaborator

NCT04714983Phase 1Suspended

DNX-2440 for Resectable Colorectal Liver Metastasis

Role: lead

NCT03714334Phase 1Terminated

DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma

Role: collaborator

NCT03178032Phase 1Completed

Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas

Role: collaborator

NCT02798406Phase 2Completed

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

Role: lead

NCT00805376Phase 1Completed

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

Role: lead

NCT02197169Phase 1Completed

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

Role: lead

NCT01956734Phase 1Completed

Virus DNX2401 and Temozolomide in Recurrent Glioblastoma

Role: collaborator

All 8 trials loaded